Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Gossamer Bio Inc

Healthcare US GOSS

0.156USD
-0.004(2.50%)

Last update at 2026-06-10T20:29:00Z

Day Range

0.140.17
LowHigh

52 Week Range

0.323.87
LowHigh

Fundamentals

  • Previous Close 0.16
  • Market Cap88.57M
  • Volume33897753
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-163.22899M
  • Revenue TTM48.47M
  • Revenue Per Share TTM0.21
  • Gross Profit TTM 48.47M
  • Diluted EPS TTM-0.75

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -170.45800M -55.63500M -179.81700M -229.37800M -234.00400M
Minority interest - - - - -
Net income -170.37000M -56.52800M -179.81700M -240.22800M -249.07600M
Selling general administrative 37.63M 36.13M 38.45M 47.61M 45.78M
Selling and marketing expenses - - 2.78M - -
Gross profit 47.47M 114.70M -4.38500M - -
Reconciled depreciation 1.00M 4.15M 4.50M 4.43M 5.17M
Ebit -163.25300M -44.11800M -166.30600M -218.59300M -216.12400M
Ebitda -162.25100M -39.96700M -161.92100M -215.43300M -214.48900M
Depreciation and amortization 1.00M 4.15M 4.38M 3.16M 1.64M
Non operating income net other - - - 3.10M 1.56M
Operating income -163.25300M -59.91900M -183.75900M -218.59300M -216.12400M
Other operating expenses 211.72M 174.62M 183.76M 218.53M 216.05M
Interest expense 10.99M 11.52M 13.51M 13.88M 19.44M
Tax provision -0.08800M 0.89M 0.00000M - -
Interest income 1.97M 1.78M 2.28M 1.58M 0.76M
Net interest income -9.01900M -9.73800M -11.44800M -12.29700M -18.67900M
Extraordinary items - - - - -
Non recurring - - - -0.06500M -0.07500M
Other items - - - - -
Income tax expense -0.08800M 0.89M 10.00M 10.85M 15.07M
Total revenue 48.47M 114.70M 0.00000M 0.00000M 0.00000M
Total operating expenses 210.72M 174.62M 183.76M 218.53M 216.05M
Cost of revenue 1.00M 4.15M 4.38M - -
Total other income expense net -7.20500M 4.28M 3.94M -10.78500M -17.88000M
Discontinued operations - - - - -
Net income from continuing ops -170.37000M -56.52800M -187.43300M -229.37800M -234.00400M
Net income applicable to common shares - - - -229.37800M -234.00400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 172.25M 315.29M 311.92M 272.45M 343.66M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 18.18M 10.03M 10.09M 6.20M 6.50M
Total liab 295.01M 285.80M 249.15M 260.37M 222.19M
Total stockholder equity -122.76000M 29.49M 62.77M -1032.22300M -811.53400M
Deferred long term liab - - - - -
Other current liab 56.54M 24.68M 31.16M 33.17M 33.71M
Common stock 0.02M 0.02M 0.02M 0.01000M 0.00800M
Capital stock 0.02M 0.02M 0.02M 0.01000M 0.00800M
Retained earnings -1438.93800M -1268.56800M -1212.04000M -1032.22300M -811.53400M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M 0.68M 1.08M
Cash 37.73M 46.07M 32.11M 111.97M 183.40M
Cash and equivalents - - - - -
Total current liabilities 63.44M 45.01M 51.60M 49.23M 39.86M
Current deferred revenue - 17.05M - - -
Net debt 164.24M 156.81M 180.35M 113.77M 1.83M
Short term debt 0.94M 0.96M 14.91M 14.60M 2.90M
Short long term debt - - 11.61M 11.61M -
Short long term debt total 201.97M 202.88M 212.46M 225.74M 185.24M
Other stockholder equity 1321.30M 1296.85M 1275.14M 0.56M -0.05300M
Property plant equipment - - - 3.98M 5.32M
Total current assets 167.64M 309.89M 306.52M 261.88M 331.78M
Long term investments - - - - -
Net tangible assets - - - 12.08M 121.46M
Short term investments 99.20M 248.44M 264.32M 143.71M 141.81M
Net receivables 12.53M 5.34M - - 0.20M
Long term debt 198.51M 197.52M 197.41M 207.70M 179.12M
Inventory - - - - -
Accounts payable 5.96M 2.32M 5.53M 1.46M 3.24M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -5.14900M 1.19M -0.35000M -0.57400M 0.04M
Additional paid in capital - - - - -
Common stock total equity - - - 0.01000M 0.00800M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -1032.22300M -811.53400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.41M 0.28M 0.62M 0.68M 1.08M
Deferred long term asset charges - - - - -
Non current assets total 4.61M 5.40M 5.40M 10.57M 11.88M
Capital lease obligations 4.40M 5.36M 3.45M 6.43M 6.12M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 156.44M 29.02M -88.14000M -0.56000M -115.80600M
Change to liabilities - - - -1.85500M -3.99800M
Total cashflows from investing activities 156.36M 29.02M -110.97000M -1.03500M -117.42700M
Net borrowings 0.00000M -12.58100M -11.61300M -5.80600M -5.80600M
Total cash from financing activities 6.42M -11.48800M 190.15M 117.09M 3.33M
Change to operating activities - - - -2.64600M 5.20M
Net income -170.37000M -56.52800M -179.81700M -229.37800M -234.00400M
Change in cash -8.34200M 13.96M -79.86400M -71.49400M -303.15300M
Begin period cash flow 46.07M 32.11M 111.97M 183.47M 486.62M
End period cash flow 37.73M 46.07M 32.11M 111.97M 183.47M
Total cash from operating activities -171.26600M -3.46800M -159.15800M -187.03200M -188.89000M
Issuance of capital stock 0.00000M 0.00000M 201.34M 119.95M 0.00000M
Depreciation 1.00M 4.15M 4.38M 4.43M 5.17M
Other cashflows from investing activities - - - -0.06500M -0.07500M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -6.88900M -5.33800M - - -
Sale purchase of stock - 0.63M 0.44M 122.90M 3.33M
Other cashflows from financing activities - 1.09M 0.89M 2.95M 3.33M
Change to netincome - - - 42.55M 32.03M
Capital expenditures 0.08M 0.00000M 0.00000M 0.47M 1.62M
Change receivables - - - - -
Cash flows other operating - - - 0.06M 8.27M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -70.97700M -302.98800M
Change in working capital -13.63000M 39.46M -14.84100M -4.45900M 0.77M
Stock based compensation 10.55M 20.62M 28.52M 42.55M 32.01M
Other non cash items 1.18M -11.17000M 2.60M -0.17700M 6.81M
Free cash flow -171.34500M -3.46800M -159.15800M -187.50700M -190.51100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GOSS
Gossamer Bio Inc		 -0.004 2.50% 0.16 - - 1.83 2.66 3.39 -0.3927
NVO
Novo Nordisk A/S		 0.62 1.47% 42.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.44 3.45% 43.14 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -10.06 2.26% 435.71 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -14.53 2.36% 601.65 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio Inc

3115 Merryfield Row, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Mr. Faheem Hasnain Co-Founder, CEO, Pres & Chairman 1958
Mr. Bryan Giraudo COO & CFO 1975
Mr. Christian Waage Exec. VP of Technical Operations & Admin. 1967
Dr. Laura L. Carter Ph.D. Chief Scientific Officer 1967
Mr. Jeff Boerneke Gen. Counsel & Sec. NA
Ms. Deanna Weber Sr. VP of HR NA
Dr. Richard Aranda M.D. Chief Medical Officer 1960
Mr. Mario Orlando Sr. VP of Commercial New Product Planning NA
Ms. Caryn L. Peterson Exec. VP of Regulatory Affairs 1959
Mr. Matt Cravets Sr. VP of Biometrics NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.